PHARMATEK · Gastroentérologie

Calculateur du score de fibrose NAFLD original

Calculer la valeur continue brute de la régression originale à six variables du score de fibrose NAFLD de 2007 à partir d’entrées vérifiées et d’unités explicites.

Révision clinique en cours

La révision clinique doit être complétée.

Cet outil fait partie de la bibliothèque PharmaTek. Son calcul reste indisponible au public jusqu’à la validation de sa formule, de ses limites et de ses sources.

Explorer les outils accessibles

Sources, population et validation

État: clinical-review-pending
Version de la méthode: Angulo 2007 original continuous NAFLD Fibrosis Score arithmetic v1: NFS = -1.675 + [0.037 × age (years)] + [0.094 × BMI (kg/m²)] + [1.13 × impaired fasting glucose or diabetes indicator (present = 1, absent = 0)] + [0.99 × AST (U/L) / ALT (U/L)] - [0.013 × platelet count (10^9/L, numerically identical to 10^3/µL)] - [0.66 × serum albumin (g/dL)]; g/L albumin is normalized to g/dL by division by 10; raw continuous output only
Population: Adults for whom applicability of the original biopsy-confirmed NAFLD source model is independently established, using age, BMI, impaired-fasting-glucose or diabetes status, AST, ALT, platelet count, and serum albumin from one verified assessment context with contemporaneous laboratory measurements, explicit units, and compatible assay identities. The original study included 733 people with biopsy-confirmed NAFLD: 480 in the estimation group and 253 in the validation group.
Limites et exclusions: Any published cutoff, threshold, low/intermediate/high classification, fibrosis category or conclusion, advanced-fibrosis classification, diagnosis, prognosis, reassurance, biopsy decision, monitoring plan, management recommendation, treatment recommendation, or other clinical decision. · Automatic equivalence between the original biopsy-confirmed NAFLD cohorts and a modern MASLD definition, another disease definition, pediatric use, or extrapolation to a population or analytical context whose applicability has not been independently established. · Mismatched or non-contemporaneous laboratory results, different assessment contexts, unverified impaired-fasting-glucose or diabetes status, unverified analyte, specimen, assay, laboratory-result, or unit identity, inferred units, or silently reinterpreted values. · Substitution of another fibrosis score, imaging result, pathology result, AST or ALT upper-limit multiple, bilirubin, INR, or any input not present in the original six-variable regression.

Origine de l’outil PharmaTek

Outil importé de la bibliothèque PharmaTek de MDose. Aucune date de révision clinique indépendante n’est documentée dans cette version.

Bibliothèque source: PharmaTek · MDose
Version importée: 4b66536936ed
État de publication: Révision clinique en cours

POURSUIVRE AVEC MDOSE

Un outil. Un premier lien.

Recevez des nouvelles des outils ou discutez d’une collaboration. L’utilisation de PharmaTek reste accessible sans laisser vos coordonnées.

Médecins et partenaires